Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Mol Cytogenet ; 7: 47, 2014.
Article in English | MEDLINE | ID: mdl-25071866

ABSTRACT

BACKGROUND: In acute myeloid leukemia (AML), the MDS1 and EVI1 complex locus - MECOM, also known as the ecotropic virus integration site 1 - EVI1, located in band 3q26, can be rearranged with a variety of partner chromosomes and partner genes. Here we report on a 57-year-old female with AML who presented with the rare translocation t(3;10)(q26;q21) involving the MECOM gene. Our aim was to identify the fusion partner on chromosome 10q21 and to characterize the precise nucleotide sequence of the chromosomal breakpoint. METHODS: Cytogenetic and molecular-cytogenetic techniques, chromosome microdissection, next generation sequencing, long-range PCR and direct Sanger sequencing were used to map the chromosomal translocation. RESULTS: Using a combination of cytogenetic and molecular approaches, we mapped the t(3;10)(q26;q21) to the single nucleotide level, revealing a fusion of the MECOM gene (3q26.2) and C10orf107 (10q21.2). CONCLUSIONS: The approach described here opens up new possibilities in characterizing acquired as well as congenital chromosomal aberrations. In addition, DNA sequences of chromosomal breakpoints may be a useful tool for unique molecular minimal residual disease target identification in acute leukemia patients.

2.
Leuk Res ; 37(10): 1363-73, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23870092

ABSTRACT

Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential for improving treatment strategies. Common MRD targets include recurrent cytogenetic abnormalities and mutations in important hematological genes; unfortunately well-characterized targets are lacking in many AL patients. Here we demonstrate a technical approach for the identification and mapping of novel clone-specific chromosomal abnormalities down to the nucleotide level. We used molecular cytogenetics, chromosome microdissection, amplification of the microdissected material, and next-generation sequencing to develop PCR-based MRD assays based on unique breakpoint sequences.


Subject(s)
Biomarkers, Tumor/genetics , Leukemia/diagnosis , Leukemia/genetics , Neoplasm, Residual/diagnosis , Neoplasm, Residual/genetics , Abnormal Karyotype , Base Sequence , Cell Line, Tumor , Chromosome Aberrations , Chromosome Banding , Chromosome Breakpoints , Chromosome Mapping , DNA-Binding Proteins/genetics , Histone-Lysine N-Methyltransferase , Humans , K562 Cells , Myeloid-Lymphoid Leukemia Protein/genetics , Nuclear Proteins/genetics , Oncogene Proteins, Fusion/genetics , Transcriptional Elongation Factors
SELECTION OF CITATIONS
SEARCH DETAIL